Stapler Innovation Addresses Current Challenges in Treating Rectal
Prolapse and Hemorrhoid Disease
NORTH HAVEN, Conn., May 17, 2010 (BUSINESS WIRE) --Covidien (NYSE: COV), a leading global provider of healthcare products,
today announced that it is entering the hemorrhoidopexy market for the
first time with EEATM
Hemorrhoid & Prolapse Stapler Set with DST SeriesTM Technology.
The new, innovative instrumentation features important advances in
hemorrhoid stapler technology and design that address what surgeons say
are their biggest challenges in performing the hemorrhoidopexy
procedure. Covidien is demonstrating the new technology at the American
Society of Colon & Rectal Surgeons annual scientific meeting this week.
Hemorrhoids are one of the most common ailments in the U.S., affecting
more than half the population, according to industry estimates. Stapled
hemorrhoidopexy, in which internal hemorrhoidal tissue is internally
stapled and excised, is considered a less painful alternative to
The EEA Hemorrhoid & Prolapse Stapler Set is designed to facilitate each
of the four steps in the hemorrhoidopexy procedure - dilation,
purse-string placement, tissue incorporation and stapling and resection.
It is the only circular stapler kit equipped with a detachable anvil
with holes, transparent winged port and clear anoscope kit and bridge.
These features allow for better tissue access and visibility and
consistent results in purse-string placement, staple formation through
DST Series Technology and tissue volume capture and incorporation.
Dr. Sang W. Lee, Associate Professor of Surgery, Section of Colon and
Rectal Surgery, New York Presbyterian Hospital, Weill-Cornell Medical
College, said, "Before Covidien's introduction of the EEA Hemorrhoid &
Prolapse Stapler Set, I think that the adoption of hemorrhoidopexy was
limited, mainly due to the limitations of the device that was available
then. Surgeons were frustrated because of poor exposure and difficulties
in properly applying the device. I think that Covidien's new hemorrhoid
stapler changes all that. It provides significantly better exposure and
clear visualization of underlying anatomic landmarks to facilitate the
accurate placement of purse-string sutures, which is the key component
of the operation. In my practice, I found that the new Covidien device
allows me to provide more consistent results with outstanding clinical
performance. I will not perform the procedure without it!"
As part of its commitment to evidence-based medicine, Covidien is
organizing a clinical study involving the EEA Hemorrhoid & Prolapse
Stapler Set with DST SeriesTechnology. Covidien also is
publishing a series of clinical experience papers.
Covidien is a leading global healthcare products company that creates
innovative medical solutions for better patient outcomes and delivers
value through clinical leadership and excellence. Covidien manufactures,
distributes and services a diverse range of industry-leading product
lines in three segments: Medical Devices, Pharmaceuticals and Medical
Supplies. With 2009 revenue of $10.7 billion, Covidien has 42,000
employees worldwide in more than 60 countries, and its products are sold
in over 140 countries. Please visit www.covidien.com
to learn more about our business.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6292814&lang=en
David T. Young, 203-492-6333
Public Relations Manager
Bruce Farmer, 508-452-4372
Coleman Lannum, CFA, 508-452-4343
Brian Nameth, 508-452-4363